<DOC>
	<DOCNO>NCT00562237</DOCNO>
	<brief_summary>Several combination H5N1 antigen concentration aluminium-hydroxide adjuvant concentration test safety capacity induce specific immune response .</brief_summary>
	<brief_title>Immunogenicity Safety Two Adjuvant Formulations Egg-Derived Pandemic Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>healthy ≥ 18 ≤ 49 year age willing able give inform consent participate influenza H5 vaccine trial past know allergic constituent vaccine serious adverse reaction previous ( influenza ) vaccination currently participate another clinical trial participate clinical trial month precede start study use medication influence immune system</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>immunogenicity</keyword>
	<keyword>safety</keyword>
	<keyword>adjuvanted pandemic vaccine</keyword>
</DOC>